| Literature DB >> 33796026 |
Zhili Tian1,2, Guohui Liang1,2, Kunli Cui3, Yayu Liang1,4, Qun Wang3, Shuangyu Lv1, Xiaoxia Cheng3, Lei Zhang3.
Abstract
RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development.Entities:
Keywords: RNAi; cancer; delivery systems; exosomes; nanoparticles
Year: 2021 PMID: 33796026 PMCID: PMC8007863 DOI: 10.3389/fphar.2021.644718
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810